Jane Street’s Definium Therapeutics DFTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-260,241
Closed -$6.43M 12549
2026
Q1
$4.92M Sell
260,241
-275,761
-51% -$4.68M ﹤0.01% 3548
2025
Q4
$7.18M Buy
536,002
+261,154
+95% +$3.23M ﹤0.01% 2726
2025
Q3
$3.24M Buy
274,848
+146,533
+114% +$1.37M ﹤0.01% 4096
2025
Q2
$833K Buy
128,315
+54,326
+73% +$357K ﹤0.01% 5968
2025
Q1
$433K Buy
73,989
+57,432
+347% +$411K ﹤0.01% 7137
2024
Q4
$115K Sell
16,557
-14,164
-46% -$97.5K ﹤0.01% 8711
2024
Q3
$175K Sell
30,721
-47,552
-61% -$331K ﹤0.01% 8732
2024
Q2
$564K Sell
78,273
-294,186
-79% -$2.57M ﹤0.01% 6825
2024
Q1
$3.5M Buy
372,459
+262,796
+240% +$1.5M ﹤0.01% 3162
2023
Q4
$401K Buy
109,663
+93,079
+561% +$280K ﹤0.01% 7151
2023
Q3
$52.2K Buy
+16,584
New +$68.2K ﹤0.01% 8144
2022
Q4
Sell
-41,563
Closed -$115K 9749
2022
Q3
$144K Buy
41,563
+28,030
+207% +$269K ﹤0.01% 8429
2022
Q2
$129K Sell
13,533
-6,320
-32% -$80K ﹤0.01% 8504
2022
Q1
$338K Buy
19,853
+8,173
+70% +$142K ﹤0.01% 8203
2021
Q4
$241K Buy
11,680
+8,278
+243% +$264K ﹤0.01% 8538
2021
Q3
$123K Sell
3,402
-38,089
-92% -$1.65M ﹤0.01% 9179
2021
Q2
$2.16M Buy
+41,491
New +$2.18M ﹤0.01% 4195

Other funds holding DFTX

Jane Street's DFTX Position: Q2 2026 in Review

Jane Street sold out of Definium Therapeutics (DFTX) in Q2 2026, closing a stake of 260,241 shares — an estimated $6.43M sold.

Jane Street first reported a position in DFTX in Q2 2021 and held it in 17 quarters. The position peaked at $7.18M in Q4 2025. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Jane Street reported no remaining Definium Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jane Street sold 260,241 Definium Therapeutics shares in Q2 2026, an estimated $6.43M.
  • Jane Street first reported a position in Definium Therapeutics in Q2 2021 and held it in 17 quarters.
  • Jane Street's Definium Therapeutics position peaked at $7.18M in Q4 2025.
  • 362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.